(Q39673935)

English

Preparation and Characterization of Apo2L/TNF-Related Apoptosis-Inducing Ligand–Loaded Human Serum Albumin Nanoparticles with Improved Stability and Tumor Distribution

scientific article published on February 1, 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Preparation and Characterization of Apo2L/TNF-Related Apoptosis-Inducing Ligand–Loaded Human Serum Albumin Nanoparticles with Improved Stability and Tumor Distribution (English)

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

0 references

0 references

6

object named as

Cheng-Hao Jin

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20669330

13 June 2024

author name string

Tae Hyung Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hai-Hua Jiang

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yu Seok Youn

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Chan Woong Park

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sung Mook Lim

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kyung Kook Tak

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hye Suk Lee

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kang Choon Lee

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

1 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

http://jpharmsci.org/article/S0022354915322991/pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20669330

13 June 2024

https://api.elsevier.com/content/article/PII:S0022354915322991?httpAccept=text/xml

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

https://api.elsevier.com/content/article/PII:S0022354915322991?httpAccept=text/plain

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Journal of Pharmaceutical Sciences

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

100

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

482-491

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Promoting apoptosis as a strategy for cancer drug discovery

1

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

2

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

3

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy

4

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety

5

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model

6

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo

7

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice

9

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Active targeting schemes for nanoparticle systems in cancer therapeutics

10

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors

12

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells.

13

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.

14

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Gamma interferon loaded onto albumin nanoparticles: in vitro and in vivo activities against Brucella abortus.

15

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Safety and efficacy of a new transpulmonary ultrasound contrast agent: Initial multicenter clinical results

17

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients

18

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinica

19

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel

20

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand.

22

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

23

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy

24

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential

25

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonins in rats

26

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Nanoparticle-based targeted drug delivery

28

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect

29

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Potential of albumin nanoparticles as carriers for interferon gamma

30

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Nanoparticle therapeutics: an emerging treatment modality for cancer

32

1 reference

10.1002/JPS.22298

https://api.crossref.org/works/10.1002/JPS.22298

13 June 2024

Identifiers

10.1002/JPS.22298

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39673935&oldid=2177856591"